Procept (PRCT) Q2 Revenue Jumps 48%

Procept BioRobotics (NASDAQ:PRCT) reported robust Q2 2025 results, with GAAP revenue surging 48.0% year-over-year to $79.2 million, exceeding analyst estimates, driven by strong U.S. and international expansion and increased consumable sales for its Aquablation therapy platform. The medical technology company also significantly narrowed its Adjusted EBITDA loss to $8.0 million from $17.9 million a year ago, and improved its GAAP gross margin to 65.0%, reflecting operational efficiencies despite increased operating expenses for commercial expansion. Management subsequently raised its full-year 2025 revenue guidance to $325.5 million, signaling continued growth momentum, though projected full-year losses underscore ongoing investments in innovation and market penetration, alongside a planned CEO transition.

Analysis

Procept BioRobotics (PRCT) delivered a robust second quarter for 2025, demonstrating significant top-line acceleration and operational leverage. The company reported a 48% year-over-year increase in GAAP revenue to $79.2 million, surpassing analyst estimates and signaling strong market adoption of its Aquablation therapy platform. This growth was driven by a 46% rise in U.S. revenue and an even faster 69% increase internationally. Critically, recurring revenue from U.S. handpieces and consumables grew 58% to $43.1 million, underscoring increasing procedural volume on its expanding installed base of 595 systems. Profitability metrics showed substantial improvement, with GAAP gross margin expanding 600 basis points to 65.0% and the adjusted EBITDA loss narrowing by more than half to $8.0 million from $17.9 million in the prior-year period. While operating expenses rose 27% to fund commercial expansion, the company's ability to narrow its net loss to $19.6 million alongside this investment is a positive indicator. Management's confidence is reflected in the upward revision of full-year 2025 revenue guidance to $325.5 million, implying sustained 45% growth. Despite projecting a full-year adjusted EBITDA loss of $35.0 million, the company's strong cash position of $305.8 million provides a sufficient runway to support its growth initiatives and the transition to a new CEO.

Key Decisions for Investors

• The strong revenue beat, significant gross margin expansion, and raised full-year guidance validate the company's growth strategy and may warrant a bullish outlook on the stock.
• Investors should closely monitor the growth rate of high-margin recurring consumables revenue and the pace of new system placements, as these are primary drivers of future profitability.
• Pay attention to the execution of the incoming CEO and progress on the WATER IV clinical trial, which represents a potential long-term catalyst for expanding the technology's addressable market beyond BPH.
• While the path to profitability is improving, the projected full-year net loss and ongoing cash burn require investors to weigh the high-growth profile against the inherent risks of an unprofitable med-tech company.